- Home
- CMP vs TSHA Comparison
CMP vs TSHA Comparison
Compare CMP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- TSHA
- Stock Information
- Founded
- CMP 1993
- TSHA 2019
- Country
- CMP United States
- TSHA United States
- Employees
- CMP N/A
- TSHA N/A
- Industry
- CMP Other Metals and Minerals
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- TSHA Health Care
- Exchange
- CMP Nasdaq
- TSHA Nasdaq
- Market Cap
- CMP 493.5M
- TSHA 397.8M
- IPO Year
- CMP 2003
- TSHA 2020
- Fundamental
- Price
- CMP $20.24
- TSHA $2.88
- Analyst Decision
- CMP Buy
- TSHA Strong Buy
- Analyst Count
- CMP 2
- TSHA 7
- Target Price
- CMP $17.50
- TSHA $7.57
- AVG Volume (30 Days)
- CMP 910.2K
- TSHA 5.0M
- Earning Date
- CMP 05-07-2025
- TSHA 05-15-2025
- Dividend Yield
- CMP N/A
- TSHA N/A
- EPS Growth
- CMP N/A
- TSHA N/A
- EPS
- CMP N/A
- TSHA N/A
- Revenue
- CMP $1,213,500,000.00
- TSHA $7,224,000.00
- Revenue This Year
- CMP $10.97
- TSHA N/A
- Revenue Next Year
- CMP $1.69
- TSHA N/A
- P/E Ratio
- CMP N/A
- TSHA N/A
- Revenue Growth
- CMP 5.81
- TSHA N/A
- 52 Week Low
- CMP $7.51
- TSHA $1.05
- 52 Week High
- CMP $20.75
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CMP 73.19
- TSHA 64.50
- Support Level
- CMP $19.00
- TSHA $2.69
- Resistance Level
- CMP $20.75
- TSHA $2.97
- Average True Range (ATR)
- CMP 0.84
- TSHA 0.23
- MACD
- CMP -0.22
- TSHA -0.02
- Stochastic Oscillator
- CMP 81.98
- TSHA 55.00
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.